Guangzhou Magpie Pharmaceuticals Co., Ltd. (MPI) is a leading biotech company in Guangzhou, China with a robust pipeline of late-stage clinical assets. MPI focuses on developing novel treatments for cerebro-cardiovascular, neurodegenerative, and mitochondrial dysfunction diseases, as well as diabetic kidney disease. Currently MPI has 7 new NCEs in development: 3 phase III, 6 phase II, and 1 phase I clinical stage assets in China; and 2 phase I-ready assets in the US.